Evidence map›Paper›PMID 40495327›Full record

ArticleThe Prostate2025

Comprehensive Genomic Profiling Testing for Castration-Resistant Prostate Cancer in Advanced Elderly Patients: A Single-Center Retrospective Cohort Study.

Takafumi Fukushima, Keisuke Goto, Yoshinori Nakano, Shinsaku Tasaka, Kyohsuke Iwane, Ryo Tasaka, Kohei Kobatake, Akihiro Goriki, Asuka Toshida, Akiko Abe and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Prostate, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Takafumi FukushimaDepartment of Urology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID 0009-0007-4434-2319
Keisuke GotoDepartment of Urology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
Yoshinori NakanoDepartment of Urology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
Shinsaku TasakaDepartment of Urology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
Kyohsuke IwaneDepartment of Urology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
Ryo TasakaDepartment of Urology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
Kohei KobatakeDepartment of Urology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
Akihiro GorikiDepartment of Urology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
Asuka ToshidaDepartment of Clinical and Molecular Genetics, Genomic Medicine Center, Hiroshima University Hospital, Hiroshima, Japan.
Akiko AbeDepartment of Clinical and Molecular Genetics, Genomic Medicine Center, Hiroshima University Hospital, Hiroshima, Japan.
Misako IshiharaDepartment of Clinical and Molecular Genetics, Genomic Medicine Center, Hiroshima University Hospital, Hiroshima, Japan.
Hikaru NakaharaDepartment of Clinical and Molecular Genetics, Genomic Medicine Center, Hiroshima University Hospital, Hiroshima, Japan.
Masanori MotonagaDepartment of Pharmaceutical Services, Hiroshima University Hospital, Hiroshima, Japan.
Kentaro TokumoDepartment of Clinical Oncology, Hiroshima University Hospital, Hiroshima, Japan.
Yasutoshi FujiiDepartment of Clinical Oncology, Hiroshima University Hospital, Hiroshima, Japan.
Hayes Clair NelsonDepartment of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
Hiroaki NiitsuDepartment of Clinical and Molecular Genetics, Genomic Medicine Center, Hiroshima University Hospital, Hiroshima, Japan.
Shinya OharaDepartment of Urology, Nakatsu Daiichi Hospital, Nakatsu, Japan.
Yuji UrabeDepartment of Gastroenterology, Hiroshima University Hospital, Hiroshima, Japan.
Wataru OkamotoDepartment of Clinical Oncology, Hiroshima University Hospital, Hiroshima, Japan.
Eiso HiyamaDepartment of Pediatric Surgery, Hiroshima University Hospital, Hiroshima, Japan.
Koji ArihiroDepartment of Anatomical Pathology, Hiroshima University Hospital, Hiroshima, Japan.
Takao HinoiDepartment of Clinical and Molecular Genetics, Genomic Medicine Center, Hiroshima University Hospital, Hiroshima, Japan.
Nobuyuki HinataDepartment of Urology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID 0000-0001-7014-6812

Funding

The authors received no specific funding for this work.
6 · The paper itself

Abstract

backgroundProstate cancer (PCa) is the second most common solid tumor in men, and its incidence is strongly dependent on age. With the aging global population, this poses a significant medical and sociodemographic issue. As treatment options for castration-resistant prostate cancer (CRPC) expand, the proportion of elderly patients with CRPC is expected to increase. Comprehensive genomic profiling (CGP) testing is becoming increasingly utilized for PCa; however, evidence on age-related outcomes or benefits is limited. This study aimed to evaluate the efficacy of CGP testing in advanced elderly patients with CRPC compared to younger patients.

methodsWe conducted a single-center, retrospective cohort study at Hiroshima University, including Japanese men aged ≥ 20 years who underwent CGP testing for CRPC between January 1, 2021, and May 31, 2024. Patients were categorized into the following two groups: the "advanced elderly group" (≥ 75 years) and the "younger group" (< 75 years). Clinical data were retrospectively extracted from medical records. CGP testing was performed using the FoundationOne® CDx, FoundationOne® Liquid CDx, Gurdant360® CDx, PleSSision Exome, or OncoGuide™ NCC Oncopanel System. Pathogenic alterations were categorized into relevant subgroups. Statistical analyzes were performed to compare patient backgrounds, genomic subgroups, and outcomes between the age groups.

resultsOverall, 85 patients (median age: 74 years) were included in the analysis, with 38 and 47 in the advanced elderly and younger groups, respectively. No significant differences were observed in baseline clinical characteristics other than age. CGP testing identified 355 pathogenic variants (140 and 215 in the advanced elderly and younger groups, respectively), with similar distributions of alteration types across the two groups. Among the subgroups, DNA repair and homologous recombination repair-related gene alterations were significantly more frequent in the younger group (p = 0.017) than in the advanced elderly group. Overall survival (OS) did not differ significantly between the age groups. However, patients who received systemic chemotherapy based on CGP testing results had significantly better OS than those who did not receive systemic therapy (p = 0.045). This trend remained significant in the advanced elderly group (p = 0.006).

conclusionsCGP testing appears to offer clinical benefits for patients with CRPC, regardless of age.

Indexed as

Prostatic Neoplasms, Castration-ResistantAgedAged, 80 and overAge FactorsGenetic TestingHumansMaleMiddle AgedRetrospective Studiesadvanced elderlycastration‐resistant prostate cancercomprehensive genome profiling testingnext‐generation sequencing

Identifiers

PMID40495327
PMCPMC12278702

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.